Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, Parallel-group Study to Assess the Pharmacokinetic Bioequivalence of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Next Previous
Trial Profile

An Open-label, Randomized, Parallel-group Study to Assess the Pharmacokinetic Bioequivalence of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guselkumab (Primary)
  • Indications Crohn's disease; Erythrodermic psoriasis; Familial adenomatous polyposis; Giant cell arteritis; Hidradenitis suppurativa; Lupus nephritis; Palmoplantar pustulosis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Pustular psoriasis; Systemic scleroderma; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development

Most Recent Events

  • 02 Feb 2022 Status changed from recruiting to completed.
  • 05 Jul 2021 Planned End Date changed from 20 Sep 2021 to 30 Dec 2021.
  • 18 Aug 2020 Planned End Date changed from 29 Jul 2020 to 20 Sep 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top